Gelonghui, November 6th: chengdu kanghua biological products (300841.SZ) stated on the investor interaction platform that the company has completed the construction of the ACYW135 group meningococcal polysaccharide vaccine raw liquid workshop and the "Kanghua biological vaccine production expansion project". They are currently in the supplementary application stage for pharmaceutical production permits, and production can begin after obtaining the production permit.
康华生物(300841.SZ)：ACYW135群脑膜炎球菌多糖疫苗原液车间等已完成建设
chengdu kanghua biological products (300841.SZ): The construction of the raw liquid workshop for ACYW135 meningococcal polysaccharide vaccine group has been completed.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
【November 2024】Has disney's predicament turned around? Pay attention to these 3 performance signals.
As the entertainment kingdom for nearly a century, Disney's status in Hollywood has gained prominence. Over 60 years of listing on the U.S. stock market, Disney